Express Healthcare
Home  »  News  »  Neuberg Diagnostics to invest upto Rs. 150 crores for North and East foray

Neuberg Diagnostics to invest upto Rs. 150 crores for North and East foray

0 493
Read Article

Appoints Dr. Amrita Singh to oversee expansion and technical operations in North and East India, North Regional Reference Lab in Delhi NCR to be operational from January 2021 

Neuberg Diagnostics will be expanding operations in Delhi and Kolkata in Q4FY21 with the recent appointment of Dr. Amrita Singh, an experienced industry expert, as Chief of Lab Services for the region. She will be overseeing the company’s expansion and technical operations in North and East India. For expansion in these two regions, the company plans to invest upto Rs.150 crores for organic and inorganic business growth.

As per a release, with more than 80 labs and 1000 touchpoints, Neuberg Diagnostics is present in India, UAE and South Africa. By onboarding the top laboratories like Bangalore based Anand Diagnostics Laboratory; Ahmedabad based Supratech Micropath; Pune based A.G Diagnostics; Chennai based Ehrlich Lab; Dubai based Minerva Lab; and South Africa based Global Lab – Neuberg has created a strong foothold in Gujarat, Tamil Nadu, Karnataka, Andhra Pradesh, Telangana, Maharashtra, and Kerala in India as well as in the UAE and South Africa.

The company aims to add another 10 labs in the next quarter and 30 labs by the end of next fiscal. It also plans to commence commercial operations in the US in the next quarter.

Giving details of their roll-out of their quality routine and referral lab testing services in North and East India, Dr. GSK Velu, Chairman and Managing Director, Neuberg Diagnostics said that additionally, they are aiming to launch new generation techniques that are deployed for diagnosing complicated diseases where deeper analysis is required.

While South and West have been their focus markets over the past three years, Dr Velu said, “We are already leaders in markets like Karnataka, Gujarat, Tamil Nadu, Kerala and South Maharashtra, and are expanding our presence in other key markets like Andhra Pradesh and Telangana and Mumbai in Maharashtra by next quarter. Now we want to be a significant player in North and East. In both the regions, we are looking for organic and inorganic growth catering to the testing needs.”

A Ganesan, Vice Chairman, Neuberg Diagnostics said, “Currently, through hospital lab management and customer walk-in centres, we already have a presence in Delhi NCR and Chandigarh. Bringing on board Dr. Amrita Singh and a senior leadership team based in Delhi and Kolkata will provide the necessary management bandwidth and technical expertise to grow our operations in North and East India over the next two years. Our northern growth will be similar to South and West India, which has enabled us to become one of the top 4 diagnostics path lab players within 3 years of our operations, since Oct 2017.”

Neuberg Diagnostics actively performs 6000+ pathological tests. Currently, it is conducting COVID-19 tests at its 10 ICMR approved labs in the country.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More